Therapeutic endocannabinoid derivatives showing an increased half-life and enhanced anti-migratory properties. These compounds retain the anti-inflammatory, anti-cancerous, anti-angiogenic, and anti-platelet aggregatory properties and are predicted to have minimal side-effects.